Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Colorectal Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Intestinal Neoplasm
Large Intestinal Neoplasm
Colorectal Neoplasm

Subtype

Colorectal Neoplasm

CI-CAN-00002404Explore in graph →

Non-malignant1,784 active trials21 approved drugs382 evidence items

NCIt: C2956
MeSH: D015179

Overview
Statistics
Survival
Genomics27
Variants & evidence382
Drugs79
Trials8604
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (357)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 226–250 of 357 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5.
· Carcinogenesis · 2015 · PMID 26442524 · validated civic_curation pubmed
Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.
· Ann Oncol · 2015 · PMID 26371285 · validated civic_curation pubmed
Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.
· Mol Cancer Ther · 2016 · PMID 27037411 · validated civic_curation pubmed
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
· Oncology · 2012 · PMID 22948721 · validated civic_curation pubmed
The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
· Cancer Genet · 2013 · PMID 23313110 · validated civic_curation pubmed
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
· Eur J Cancer · 2015 · PMID 25673558 · validated civic_curation pubmed
Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.

Showing 226–250 of 357 publications

← Previous
1
…
9
10
11
…
15
Next →

· Clin Cancer Res · 2015 · PMID 25589621 · validated civic_curation pubmed

Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.

· Oncology · 2016 · PMID 27404270 · validated civic_curation pubmed

SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.

· Br J Cancer · 2002 · PMID 12237773 · validated civic_curation pubmed

HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.

· Clin Colorectal Cancer · 2017 · PMID 28223103 · validated civic_curation pubmed

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

· J Clin Oncol · 2008 · PMID 18316791 · validated civic_curation pubmed

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

· N Engl J Med · 2012 · PMID 23094721 · validated civic_curation pubmed

PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.

· Int J Cancer · 2007 · PMID 17590872 · validated civic_curation pubmed

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

· J Clin Oncol · 2008 · PMID 19001320 · validated civic_curation pubmed

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.

· Br J Cancer · 2009 · PMID 19603024 · validated civic_curation pubmed

BRAF mutation in metastatic colorectal cancer.

· N Engl J Med · 2009 · PMID 19571295 · validated civic_curation pubmed

The DCC protein and prognosis in colorectal cancer.

· N Engl J Med · 1996 · PMID 8929264 · validated civic_curation pubmed

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.

· Invest New Drugs · 2016 · PMID 26666244 · validated civic_curation pubmed

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.

· Lancet Gastroenterol Hepatol · 2016 · PMID 28404093 · validated civic_curation pubmed

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

· Cancer Res · 2009 · PMID 19223544 · validated civic_curation pubmed

PIK3CA mutations predict local recurrences in rectal cancer patients.

· Clin Cancer Res · 2009 · PMID 19903786 · validated civic_curation pubmed

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.

· Lancet Oncol · 2019 · PMID 30857956 · validated civic_curation pubmed

Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

· Target Oncol · 2020 · PMID 33068284 · validated civic_curation pubmed

Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.

· JCO Precis Oncol · 2022 · PMID 36315917 · validated civic_curation pubmed

Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

· JCO Precis Oncol · 2022 · PMID 36409971 · validated civic_curation pubmed